Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086216 | 1.00 | ALOX5 (0.44) | ALOX5NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL8610041 | 0.92 | ALOX5 (0.51) | ALOX5NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL8309230 | 0.92 | ALOX5 (0.51) | ALOX5NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL8309228 | 0.92 | ALOX5 (0.51) | ALOX5NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL4729172 | 0.80 | NPC1 (0.45) | ALOX5NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8609409 | 0.80 | NPC1 (0.45) | ALOX5NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8607936 | 0.80 | ALOX5 (0.44) | ALOX5NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL4729170 | 0.80 | NPC1 (0.45) | ALOX5NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8941348 | 0.80 | PPARG (0.48) | ALOX5NPC1RAB9AEPHX2LMNA | |
| SCHEMBL8659861 | 0.79 | MAPT (0.51) | ALOX5NPC1RAB9AEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832078-B1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-10-20 | — | — | EP | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0832078-B1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ALOX5 1721/4885NPC1 78/4885RAB9A 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.